|
MAD2L1BP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.72690001082532E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.86390000392834E-08 |
| Normal-vs-Stage2 |
1.72165999999807E-05 |
| Normal-vs-Stage3 |
1.16639999991897E-07 |
| Normal-vs-Stage4 |
4.20789999955318E-07 |
| Stage1-vs-Stage2 |
5.217200E-01 |
| Stage1-vs-Stage3 |
4.003400E-01 |
| Stage1-vs-Stage4 |
1.894800E-01 |
| Stage2-vs-Stage3 |
9.910800E-01 |
| Stage2-vs-Stage4 |
6.118600E-01 |
| Stage3-vs-Stage4 |
5.549800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.44620000209051E-08 |
| Normal-vs-AfricanAmerican |
1.54230999999116E-05 |
| Normal-vs-Asian |
2.960000E-02 |
| Caucasian-vs-AfricanAmerican |
3.732000E-01 |
| Caucasian-vs-Asian |
6.665500E-02 |
| AfricanAmerican-vs-Asian |
4.862100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.10619999511053E-08 |
| Normal-vs-Female |
1.01579999967072E-08 |
| Male-vs-Female |
5.509200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.88769999976257E-07 |
| Normal-vs-Age(41-60Yrs) |
2.92039999960636E-08 |
| Normal-vs-Age(61-80Yrs) |
3.95919996787342E-09 |
| Normal-vs-Age(81-100Yrs) |
9.288200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.942000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.673900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.178400E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.052400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.434200E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.743900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.563400E-01 |
| Classical-VS-Follicular |
5.5083999999983E-05 |
| Classical-VS-Other |
4.241800E-01 |
| Classical-VS-Normal |
1.70991999999259E-05 |
| Tall-VS-Follicular |
1.018130E-02 |
| Tall-VS-Other |
4.844200E-01 |
| Tall-VS-Normal |
4.435100E-04 |
| Follicular-VS-Other |
8.965000E-01 |
| Follicular-VS-Normal |
2.95300450758873E-11 |
| Other-VS-Normal |
9.769600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.41810005141963E-09 |
| Normal-vs-N1 |
1.9008999996295E-07 |
| N0-vs-N1 |
9.825900E-02 |
|
|
